Prosensa to Appoint Michael Wyzga to Supervisory Board

Prosensa to Appoint Michael Wyzga to Supervisory Board

Leiden, The Netherlands, April 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding
N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on rare
diseases with a high unmet medical need, today announced that Michael S. Wyzga
has been nominated for appointment to its Supervisory Board at the next
shareholders' meeting, scheduled for June 17, 2014.

"We welcome Michael  as an  instrumental addition to  our Supervisory  Board," 
said  Hans  Schikan,  Prosensa's  CEO.  "Michael's  extensive  financial  and 
transactional expertise will support the company significantly in our  efforts 
to bring  much-needed, life-saving  treatments for  rare genetic  diseases  to 
patients. His  long-term  tenure  at  Genzyme,  one  of  the  most  successful 
companies in  the  rare disease  space,  will  be invaluable  as  we  continue 
developing therapies for  boys with Duchenne  muscular dystrophy and  building 
our company."

Mr. Wyzga most  recently served as  President and Chief  Executive Officer  of 
Radius Health. Prior to joining Radius, Mr. Wyzga was Executive Vice President
and Chief Financial  Officer of  Genzyme Corporation until  its $20.1  billion 
acquisition by  Sanofi in  April 2011.  He  joined Genzyme  in 1998  and  held 
primary responsibility for the  company's financial management worldwide.  Mr. 
Wyzga currently serves on the board of directors for OncoMed  Pharmaceuticals, 
Akebia Therapeutics and Idenix Pharmaceuticals.

"Michael's corporate leadership experience in rare diseases makes him an ideal
fit for Prosensa, and his contribution will  be vital as the company works  to 
successfully advance  its DMD  drug pipeline,"  said David  Mott, Chairman  of 
Prosensa's Supervisory Board.

"I am pleased to join Prosensa at  such a significant moment in the  company's 
history and  look  forward  to  working  alongside  a  world-class  team  with 
exceptional leadership in rare diseases," said Michael Wyzga. "It is an  honor 
to be able to share my experience  and contribute to the future direction  and 
growth of a  company working so  diligently to find  a therapeutic option  for 
boys with this devastating disease."

Notes to editors

About Prosensa Holding N.V.

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the
discovery and development of RNA-modulating therapeutics for the treatment of
genetic disorders. Its primary focus is on rare neuromuscular and
neurodegenerative disorders with a large unmet medical need, including
Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington's

Prosensa's current portfolio includes six compounds for the treatment of DMD,
all of which have received orphan drug status in the United States and the
European Union. The compounds use an innovative technique called exon-skipping
to provide a personalized medicine approach to treat different populations of
DMD patients.

CONTACT: Prosensa Holding N.V.
         Celia Economides, Senior Director, IR & Corporate Communications
         Phone: +1 917 941 9059

Prosensa Holding B.V. Logo
Press spacebar to pause and continue. Press esc to stop.